Skip to main content
. Author manuscript; available in PMC: 2017 Jul 26.
Published in final edited form as: Nanoscale. 2016 Mar 10;8(25):12668–12682. doi: 10.1039/c5nr09071g

Fig. 1.

Fig. 1

Model structure of PSMA-targeted protein MRI contrast agents for the molecular imaging of PSMA in prostate cancer. Each PSMA targeting peptide (red) was fused at the C-terminal of PEGylated ProCA32 (gray) using flexible peptide linkers (blue).